Privia Health Group, Inc. (PRVA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | (m) | |
| Stock-based compensation | 75.75M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 44.88M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $75.75M | $44.88M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $75.20M | $36.44M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $71.07M | $34.23M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $70.89M | $28.20M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $67.02M | $19.61M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $62.57M | $21.38M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $56.68M | $16.98M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $53.07M | $13.15M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $48.77M | $12.88M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $43.62M | $14.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $37.10M | $20.65M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $34.60M | $21.48M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $38.64M | $11.37M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $47.86M | $-861.00K | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $67.36M | $-19.12M | $500.00K | (m) | (m) | -38.24× | Reported |
| 2022-09-30 | (m) | (m) | $83.25M | $-40.72M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $94.22M | $-48.95M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $278.31M | $-236.89M | $1.00M | (m) | (m) | -236.89× | Reported |
| 2021-12-31 | (m) | (m) | $253.53M | $-217.44M | $1.10M | (m) | (m) | -197.67× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $484.00K | $25.38M | $1.90M | (m) | (m) | 13.36× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $207.00K | $16.06M | $4.00M | (m) | (m) | 4.02× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |